Followers | 28 |
Posts | 4449 |
Boards Moderated | 1 |
Alias Born | 09/22/2006 |
Monday, April 14, 2014 7:49:55 PM
Roche will publish its Sales Results for the 1st Quarter of 2014 prior to the opening of the Swiss Stock Exchange on Tuesday April 15th, 2014.
07:00 CEST / 06:00 BST / 01:00 AM EDT / 22:00 PM PDT (evening before)
Release will be e-mailed and posted on the Roche IR website click here.
Presentation slides will be posted on the Roche IR website click here.
We would like to invite all interested parties to dial in as outlined below:
14:00 – 15:15 CEST / 13:00 – 14:15 BST
08:00 – 09:15 AM EDT / 05:00 – 06:15 AM PDT
Conference call will start with presentations by senior management followed by a Q&A session (live access to the speakers).
Presenters:
Severin Schwan, CEO Roche Group
Alan Hippe, Chief Financial and IT Officer
Daniel O'Day, COO Pharmaceuticals
Roland Diggelmann, COO Diagnostics
Please dial in to the conference 10-15 min prior to the scheduled start , using the following numbers:
+41 (0) 58 310 5000 (Europe and ROW)
+44 (0) 203 059 5862 (UK)
+1 (1) 631 570 5613 (USA)
To expedite the registration process on the day of the conference call, you may pre-register for the event by clicking here.
Alternatively a live audio webcast can be accessed via ir.roche.com.
A replay of the conference call will be available one hour after the conference call, for 48 hours. Access is by dialing:
+41 (0) 91 612 4330 (Europe and ROW)
+44 (0) 207 108 6233 (UK)
+1 (1) 631 982 4566 (USA)
and will be asked to enter the ID 18061 followed by the # sign.
A replay of the webcast will be available on demand at ir.roche.com.
Services
Investor Relations team
Send e-mail
RSS-feeds
Subscribe to IR News
Roche Finance Info System
You are here: Investors Investor Updates Reminder: Invitation to Roche's First Quarter Sales 2014 Conference Call Share via emailShare on FacebookShare on TwitterShare on LinkedInShare on Google+
© 2014 F. Hoffmann-La Roche Ltd03.04.2014
http://www.roche.com/investors/ir_update/inv-update-2014-04-08.htm
The more you know, the less you don't know.
Recent HALO News
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/25/2024 08:00:51 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/24/2024 08:05:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/18/2024 10:49:57 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/18/2024 08:01:16 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/17/2024 08:03:48 PM
- Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO™ with ENHANZE® for People with Relapsing and Primary Progressive Multiple Sclerosis • PR Newswire (US) • 09/13/2024 05:30:00 PM
- Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza™ With ENHANZE® for Multiple Types of Cancer • PR Newswire (US) • 09/13/2024 12:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/12/2024 09:56:59 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/12/2024 08:12:07 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/11/2024 08:05:49 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/10/2024 08:16:18 PM
- Halozyme to Present at Upcoming Investor Conferences • PR Newswire (US) • 08/28/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/27/2024 11:49:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/21/2024 10:03:29 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/21/2024 08:11:18 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/20/2024 08:16:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/15/2024 08:59:35 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/15/2024 08:31:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 08:57:27 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/14/2024 08:08:38 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/13/2024 08:19:53 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 08:07:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 08:03:09 PM
- HALOZYME REPORTS SECOND QUARTER 2024 FINANCIAL AND OPERATING RESULTS • PR Newswire (US) • 08/06/2024 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/24/2024 09:48:14 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM